Investigating and Comparing the Association of Fatty Liver with Tamoxifen and Letrozole in Premenopausal Patients with Breast Cancer

Phase 2

Recruiting

• Conditions: Condition 1: Breast Cancer. Condition 2: Fatty Liver.; Malignant neoplasm of breast; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20221126056616N1
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Premenopausal breast cancer patients (Progesterone receptor or Estrogen receptor positive).

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of fatty liver. Timepoint: 6 months after taking tamoxifen and letrozole drugs. Method of measurement: Ultrasound.